<DOC>
	<DOCNO>NCT00812175</DOCNO>
	<brief_summary>In international non-interventional study safety clinical data concern treatment patient suffer Hepatocellular Carcinoma ( HCC ) collect .</brief_summary>
	<brief_title>Global Investigation Therapeutic Decisions Hepatocellular Carcinoma Its Treatment With Sorafenib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Outpatients histologically/cytologically document radiographically diagnose unresectable HCC candidate systemic therapy decision treat Nexavar make . Radiographic diagnosis HCC NIS , need typical finding HCC radiographic method i.e . multidimensional , dynamic CT , CT hepatic arteriography ( CTHA ) /CT arterial portography ( CTAP ) , MRI . Patients must sign informed consent form Patients must life expectancy least 8 week Exclusion criterion must follow approve local product information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>HCC</keyword>
	<keyword>Sorafenib</keyword>
</DOC>